CryoPort, Inc. (NASDAQ:CYRX) Stock Rated “Moderate Buy” by Wall Street Brokerages

Shares of CryoPort, Inc. (NASDAQ:CYRX) have been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $21.69.

A number of research analysts have recently commented on the stock. Robert W. Baird set a $26.00 price objective on shares of CryoPort in a research note on Tuesday, October 13th. Roth Capital reissued a “buy” rating and issued a $21.00 target price on shares of CryoPort in a research report on Friday, August 7th. Guggenheim boosted their target price on shares of CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Needham & Company LLC boosted their target price on shares of CryoPort from $19.00 to $28.00 and gave the company a “buy” rating in a report on Friday. Finally, Piper Sandler raised shares of CryoPort to a “buy” rating in a research report on Tuesday, October 13th.

CryoPort Stock Up 19.0%

Shares of NASDAQ:CYRX opened at $19.10 on Tuesday. The company has a market cap of $967.40 million, a P/E ratio of -19.69 and a beta of 1.89. The business has a fifty day simple moving average of $16.98 and a 200-day simple moving average of $13.46. CryoPort has a 52 week low of $7.61 and a 52 week high of $19.53.

CryoPort (NASDAQ:CYRX) last released its earnings results on Thursday, November 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). CryoPort had a negative return on equity of 8.20% and a negative net margin of 21.46%. The business had revenue of $50.22 million for the quarter, compared to analysts’ expectations of $48.66 million. Sell-side analysts expect that CryoPort will post -0.83 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Jerrell Shelton sold 28,800 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total transaction of $429,408.00. Following the completion of the sale, the chief executive officer directly owned 1,201,814 shares in the company, valued at $17,919,046.74. This represents a 2.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CryoPort

A number of institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP acquired a new position in shares of CryoPort in the second quarter worth about $8,398,000. Squarepoint Ops LLC raised its holdings in shares of CryoPort by 685.1% during the second quarter. Squarepoint Ops LLC now owns 368,424 shares of the company’s stock valued at $5,784,000 after acquiring an additional 321,497 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of CryoPort by 376.7% during the third quarter. Russell Investments Group Ltd. now owns 399,047 shares of the company’s stock valued at $6,943,000 after acquiring an additional 315,343 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of CryoPort during the second quarter valued at approximately $3,363,000. Finally, Granahan Investment Management LLC lifted its position in shares of CryoPort by 475.0% in the 1st quarter. Granahan Investment Management LLC now owns 231,138 shares of the company’s stock valued at $1,914,000 after acquiring an additional 190,938 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

CryoPort News Roundup

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $50.2 million, topping estimates of $48.66 million. Commercial cell and gene therapy revenue grew 20%; Cryoport supported a record 788 global clinical trials and 23 commercially approved therapies. Cryoport Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to $197 million–$199 million, a key catalyst behind the favorable reaction to results. CryoPort Shares Rise After Q3 Revenue Beat, 2026 Guidance Raise
• Positive Sentiment: Analyst actions added support: Needham raised its price target to $28 from $19 and reiterated Buy, while KeyCorp lifted its target to $20 from $17 and maintained an Overweight rating. Needham Adjusts Price Target KeyCorp Rating
• Negative Sentiment: Adjusted earnings were a loss of $0.25 per share, missing consensus estimates of a $0.18–$0.19 loss and widening from a $0.18 loss a year earlier. The earnings shortfall may temper optimism around the revenue growth and raised outlook. CryoPort Reports Q3 Loss, Tops Revenue Estimates

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.